5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
SELL | SELL | SELL | SELL | SELL |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 2.36▼ | 2.36▼ | 2.36▼ | 2.39▼ | 2.44▼ |
MA10 | 2.38▼ | 2.38▼ | 2.38▼ | 2.37▼ | 2.76▼ |
MA20 | 2.37▼ | 2.38▼ | 2.39▼ | 2.48▼ | 3.82▼ |
MA50 | 2.41▼ | 2.37▼ | 2.36▼ | 2.86▼ | 8.38▼ |
MA100 | 2.36▼ | 2.38▼ | 2.46▼ | 4.35▼ | 36.16▼ |
MA200 | 2.47▼ | 2.76▼ | 2.78▼ | 7.37▼ | 62.20▼ |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | -0.002▼ | -0.006▼ | -0.007▼ | 0.026▲ | 0.410▲ |
RSI | 42.215▼ | 43.434▼ | 44.194▼ | 36.113▼ | 27.672▼ |
STOCH | 8.824▼ | 29.216 | 29.216 | 66.684 | 12.739▼ |
WILL %R | -100.000▼ | -83.333▼ | -83.333▼ | -39.914 | -95.402▼ |
CCI | -130.480▼ | -87.302 | -89.157 | 20.467 | -100.711▼ |
Monday, August 04, 2025 07:10 PM
NYSE Texas will move into the historic Old Parkland office campus in Oak Lawn. With a signed lease in hand, the Big Board’s local branch is expected to open ...
|
Monday, July 28, 2025 01:00 AM
ATLANTA, July 28, 2025 (GLOBE NEWSWIRE) -- Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company, focused on developing novel products for the treatment ...
|
Sunday, July 27, 2025 10:00 PM
ATLANTA, July 28, 2025 (GLOBE NEWSWIRE) -- Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company, focused on developing novel products for the treatment ...
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
19/08/25 | 2.35 | 2.43 | 2.31 | 2.34 | 56,500 |
18/08/25 | 2.34 | 2.445 | 2.34 | 2.38 | 59,500 |
15/08/25 | 2.38 | 2.4332 | 2.33 | 2.375 | 49,841 |
14/08/25 | 2.37 | 2.44 | 2.30 | 2.43 | 63,100 |
13/08/25 | 2.45 | 2.526 | 2.40 | 2.42 | 88,600 |
12/08/25 | 2.40 | 2.525 | 2.40 | 2.44 | 123,670 |
11/08/25 | 2.35 | 2.43 | 2.33 | 2.40 | 61,701 |
08/08/25 | 2.26 | 2.35 | 2.20 | 2.35 | 110,100 |
07/08/25 | 2.22 | 2.28 | 2.21 | 2.245 | 55,800 |
06/08/25 | 2.41 | 2.44 | 2.14 | 2.27 | 167,769 |
|
|
||||
|
|
||||
|
|